Articles tagged "Immunosuppression"

2018 American Transplant Congress
Human CD8⁺CD28^– T Cells Driven In Vitro by IL-15 Suppress in Allo-Specific Manner Partially through PD-1:PD-L1 Pathway
F. Feng,^1,2 G. Liu,¹ P. Zhu,¹ M. Zhu,¹ X. Lu,¹ J. Liu,² X. Luo,³ Y. Liu,¹ Y. Yu.²
¹Department of Immunology, School of Basic Medical Science, Southern Medical University, Guangzhou, Guangdong, China; ²Department of Urology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China; ³Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL.
Background: CD8+CD28- T suppressor cells (Ts) have emerged as an important modulator of alloimmunity, but the in vitro inducibility of Ts subsets is rather unclear.…
2018 American Transplant Congress
Once-Daily versus Twice-Daily Tacrolimus in De Novo Living Kidney Transplantation Patients: A Multicenter, Parallel Group, Open-Label, 5-Year Randomized Noninferiority Trial
Y. Kakuta,¹ M. Okumi,¹ K. Unagami,² M. Furusawa,¹ H. Ishida,¹ K. Tanabe.¹
¹Urology, Tokyo Women's Medical University, Tokyo, Japan; ²Nephrology, Tokyo Women's Medical University, Tokyo, Japan.
BackgroundTacrolimus is available as twice-daily (TAC-BID) and once-daily (TAC-QD) formulations. Findings from pharmacokinetic and short-term trials are available. However, results from long-term trials are limited.We…
2018 American Transplant Congress
Triptolide Reduces the Required Dose of Tacrolimus by Attenuating Inflammation, Enhancing Immunosuppression, and Increasing Donor Chimerism in a Heterotopic Hindlimb Transplantation Model
C. Gu, F. Liu, J. Yang.
Plastic and Reconstructive Surgery, Shanghai Ninth Hospital, Shanghai, China.
Background: Induction of tolerance and minimizing the toxicity of immuno- suppression are two fundamental goals in vascularized composite allotrans- plantation. Accumulating data indicate that triptolide…
2018 American Transplant Congress
Long-Term Effects of Ketoconazole in Rapid Tacrolimus Metabolizers Post-Renal Transplantation
J. Ching,¹ S. Anders,¹ M. Janusek,¹ L. Hutchinson,¹ A. Freeman,¹ U. Patel,¹ A. Mohammed,⁴ H. Bohorquez.^2,3
¹Department of Pharmacy, Ochsner Clinical Foundation, New Orleans, LA; ²Multi-Organ Transplant Institute, Ochsner Clinical Foundation, New Orleans, LA; ³The University of Queensland School of Medicine, Ochsner Clinical School, New Orleans, LA; ⁴Academic Center, Ochsner Clinical Foundation, New Orleans, LA.
Introduction: Genetic polymorphisms in cytochrome P-450 enzymes can cause variations in tacrolimus (tac) metabolism. Ketoconazole (keto), a potent CYP450 and P-glycoprotein inhibitor, can be used…
2018 American Transplant Congress
Immunosuppression Does Not Affect Adverse Pathological Outcomes in Men Who Underwent Radical Prostatectomy
M. Eltemamy, A. Elshafei, Y. Nyame, A. Crane, A. Wee, V. Krishnamurthi, E. Klein, S. Jones.
Cleveland Clinic, Cleveland.
Introduction: The impact of imuunosuppression (IS) on biological aggressiveness of cancer prostate (PCa) is unclear. We aim to assess the adverse pathological (AP) outcomes in…
2018 American Transplant Congress
The Net State of Immunosuppression in Septuagenarian Liver Transplant Recipients: Balancing Rejection and Infection Risks
J. Casale,¹ J. Clark,¹ B. Ravichandran,¹ J. LaMattina.²
¹Pharmacy, University of Maryland Medical Center, Baltimore; ²University of Maryland School of Medicine, Baltimore.
Purpose: Careful patient selection and perioperative management have allowed for successful liver transplantation in elderly patients. Elderly patients may be more susceptible to the infectious…
2018 American Transplant Congress
Tacrolimus-Based Maintenance Immunosuppression Decreases the Number of Peripheral Blood Transitional B Cells in Nonhuman Primates
J. Paster, K. Pruner, M. Hanekamp, J. O., W. Sommer, K. Robins, A. Bean, G. Benichou, J. Madsen.
Center for Transplantation Sciences, Mass General Hospital, Boston, MA.
IntroductionElevated frequencies of transitional B cells have been reported in patients tolerant of renal allografts, as defined by stable graft function after withdrawal of immunosuppression…
2018 American Transplant Congress
Superiority of Early Everolimus-Based Quadruple Immunosuppression versus Standard Triple Therapy after Lung Transplantation: 12 Months Results from Prospective 4EVERLUNG Study in Germany
J. Gottlieb, C. Neurohr, J. Müller-Quernheim, H. Wirtz, B. Sill, H. Wilkens, V. Besa, C. Knosalla, M. Junge, C. Capusan, M. Strüber.
Klinik, Hannover, Germany; Klinik, München, Germany; Klinik, Freiburg, Germany; Klinik, Leipzig, Germany; Klinik, Hamburg, Germany; Klinik, Homburg, Germany; Klinik, Essen, Germany; Klinik, Berlin, Germany; Novartis Pharma, Nürnberg, Germany; Novartis Pharma, Nürnberg, Germany; Klinik, Hannover, Germany.
The 4Everlung trial was designed to evaluate the benefit of early everolimus (EVR)-based quadruple low immunosuppressive (IS) regimen on kidney function (RF) after LTx.4EVERLUNG is…
2018 American Transplant Congress
Precision Medicine for Determining the Efficacy of a Novel Belatacept Regimen
J. Shoji, J. Leung, E. Tavares, Q. Tang, F. Vincenti.
Transplant Nephrology, UCSF, San Francisco, CA.
IntroBelatacept is increasingly used as maintenance immunosuppression to improve long term outcomes in kidney transplant. Since acute rejection in patients on belatacept have been noted…
2018 American Transplant Congress
IL-21 Regulates Creation of Tertiary Lymphoid Organs in Chronic Allograft Rejection
J. Breidenbach, C. Baum, P. Schroder, S. Stepkowski.
Medical Microbiology and Immunology, University of Toledo College of Medicine and Life Science, Toledo, OH.
Background: IL-21 is a cytokine expressed almost exclusively by cells of the adaptive immune system, making it an attractive target for reducing chronic allograft rejection…